<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267733</url>
  </required_header>
  <id_info>
    <org_study_id>1406014244</org_study_id>
    <nct_id>NCT02267733</nct_id>
  </id_info>
  <brief_title>Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients</brief_title>
  <acronym>SHIVERING</acronym>
  <official_title>Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pilot Study utilizing high dose trivalent influenza vaccine dose in a booster dosing
      schedule for patients with monoclonal gammopathies stratified by disease status
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we will administer FluzoneÂ® High-Dose vaccine with a planned booster to
      patients with monoclonal gammopathies (stratified by requirement for therapy) irrespective of
      age. All patients will receive an initial vaccine followed by a booster vaccine 30 days (+/-
      7 days) later and will then be followed for outcomes until the end of flu season.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Disease Control</measure>
    <time_frame>up to 10 months</time_frame>
    <description>Lack of disease progression requiring therapy as measured by International Myeloma Working Group criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influenza related morbidity rate</measure>
    <time_frame>up to 10 months</time_frame>
    <description>Measure the rate of influenza related morbidity at the end of the flu season</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serologic Protection Rate after initial vaccine</measure>
    <time_frame>30 days post vaccine</time_frame>
    <description>Evaluate rates of serologic protection (defined as HAI titer &gt; 40) following initial vaccine dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serologic Protection Rate after initial vaccine</measure>
    <time_frame>30 days post booster</time_frame>
    <description>Evaluate rates of serologic protection (defined as HAI titer &gt; 40) following booster vaccine dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell response</measure>
    <time_frame>30 day post initial vaccine</time_frame>
    <description>Measurement of CD4+/CD8+, NK cells and influenza-specific T cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell response</measure>
    <time_frame>30 day post booster</time_frame>
    <description>Measurement of CD4+/CD8+, NK cells and influenza-specific T cell</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Influenza</condition>
  <condition>Gammopathy</condition>
  <arm_group>
    <arm_group_label>Early Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients not requiring anti-tumor therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease Requiring Anti-tumor therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that have disease requiring anti-tumor therapy at any time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzone</intervention_name>
    <description>Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration</description>
    <arm_group_label>Early Disease</arm_group_label>
    <arm_group_label>Disease Requiring Anti-tumor therapy</arm_group_label>
    <other_name>Fluzone High Dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and voluntarily sign an informed consent document

          -  Age &gt;= 18 years at the time of signing the informed consent form

          -  Diagnosis of any monoclonal gammopathy; Monoclonal Gammopathy of Undetermined
             Significance (MGUS), asymptomatic/ active multiple myeloma, asymptomatic / active
             Waldenstrom Macroglobulinemia (WM)

        Exclusion Criteria:

          -  An serious egg allergy or prior serious adverse reaction to an influenza vaccine

          -  Use of any other influenza vaccine for the 2014 to 2015 flu season

          -  Women who are pregnant or plan to become pregnant in the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Branagan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2014</study_first_submitted>
  <study_first_submitted_qc>October 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

